Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

China HeadAche DIsorders RegiStry

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

It is planned to include 10000 patients. In the China HeadAche DIsorders RegiStry CHAIRS）, patients aged over 12 years with primary headache and medication-overuse headache(MOH) were collected. The biomarkers, imaging features, cognition, genetic characteristics, ocial and demographic data, medical data, therapeutics used, and outcome of headache-related diseases were studied, and long-term follow-up was planned.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Age ≥ 12 years old,Any gender; 2. The first onset age of primary headache was less than 50 years old(Age \<65 years at first diagnosis of chronic migraine); 3. patients with primary headache (migraine, tension headache and other types of primary headache) or primary headache complicated with MOH according to ICHD-3; 4. Sign the willing to sign a consent form form. Who Should NOT Join This Trial: 1. According to the ICHD-3 diagnostic criteria, there are still headaches directly related to secondary factors (except drug overuse) at the time of enrollment; 2. Those who cannot be diagnosed as primary headache or primary headache combined with medication overuse headache according to ICHD-3; 3. According to DSM-V diagnostic criteria, patients with severe mental diseases (such as schizophrenia, mental disorders associated with mental retardation, etc.); 4. Patients with severe organic diseases, such as malignant tumors, and the expected survival time is less than 1 year; 5. Pregnant,planning pregnancy or Lactating women; 6. Subjects participating in other clinical trials; 7. Unable to cooperate to complete the follow-up due to geographical or other reasons Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Age ≥ 12 years old,Any gender; 2. The first onset age of primary headache was less than 50 years old(Age \<65 years at first diagnosis of chronic migraine); 3. patients with primary headache (migraine, tension headache and other types of primary headache) or primary headache complicated with MOH according to ICHD-3; 4. Sign the informed consent form. Exclusion Criteria: 1. According to the ICHD-3 diagnostic criteria, there are still headaches directly related to secondary factors (except drug overuse) at the time of enrollment; 2. Those who cannot be diagnosed as primary headache or primary headache combined with medication overuse headache according to ICHD-3; 3. According to DSM-V diagnostic criteria, patients with severe mental diseases (such as schizophrenia, mental disorders associated with mental retardation, etc.); 4. Patients with severe organic diseases, such as malignant tumors, and the expected survival time is less than 1 year; 5. Pregnant,planning pregnancy or Lactating women; 6. Subjects participating in other clinical trials; 7. Unable to cooperate to complete the follow-up due to geographical or other reasons

Treatments Being Tested

BEHAVIORAL

Medicine Overuse Headache/New Daily Persistent Headache

At the end of the 24th month visit, the patient is free to choose whether to conduct a face-to-face visit once a year until death.

BEHAVIORAL

Episodic Migraine and Chronic Migraine

long-term follow-up

BEHAVIORAL

Patients with other types of primary headache

No collection Brain imaging、Cognitive function test、Biological sample

DRUG

Yangxue Qingnao Granules (Pills)

Participants who, in routine clinical practice, were prescribed Yangxue Qingnao Granules/Pills for acute headache relief and/or preventive management were enrolled. Treatment initiation, dosing, frequency, and duration were determined by the treating physician and the patient and were not assigned by the study protocol. During the 12-week observation period, participants were followed and outcomes were recorded, including relief of up to four headache episodes (for those using the medication for acute treatment) and longitudinal symptom measures at weeks 4, 8, and 12 (for those receiving preventive management).

BIOLOGICAL

Erenumab

Participants who received eptinezumab for migraine prophylaxis in routine clinical practice were included. Treatment decisions (including whether to initiate eptinezumab, the selected dose \[e.g., 100 mg or 300 mg\], infusion interval, and duration) were made by the treating physician in consultation with the patient, and were not assigned by the study protocol. Patients were followed prospectively/retrospectively according to routine clinic visits, with outcome assessments captured at approximately 4-week intervals during the 12-week observation window (and additional follow-up when available).

BIOLOGICAL

Eptinezumab

Participants who received eptinezumab for migraine prophylaxis in routine clinical practice were included. Treatment decisions (including whether to initiate eptinezumab, the selected dose \[e.g., 100 mg or 300 mg\], infusion interval, and duration) were made by the treating physician in consultation with the patient, and were not assigned by the study protocol. Patients were followed prospectively/retrospectively according to routine clinic visits, with outcome assessments captured at approximately 4-week intervals during the 12-week observation window (and additional follow-up when available).

Locations (20)

Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Chaoyang Hospital
Beijing, Beijing Municipality, China
Chongqing People's Hospital
Chongqing, Chongqing Municipality, China
Fujian Provincial Hospital
Fuzhou, Fujian, China
The First Affiliated Hospital of Guangxi University of Chinese Medicine
Nanning, Guangxi, China
The First People's Hospital of Zunyi
Zunyi, Guizhou, China
Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine
Qionghai, Hainan, China
Zhangjiakou First Hospital
Zhangjiakou, Hebei, China
Luohe Central Hospital
Luohe, Henan, China
Luoyang Central Hospital
Luoyang, Henan, China
The Second Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
The 7th People's Hospital of Zhengzhou
Zhengzhou, Henan, China
Changzhou First People's Hospital
Changzhou, Jiangsu, China
Jiujiang First People's Hospital
Jiujiang, Jiangxi, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Huludao Central Hospital
Huludao, Liaoning, China
Zibo Municipal Hospital
Zibo, Shandong, China
Dachuan District People's Hospital
Dazhou, Sichuan, China
Deyang People's Hospital
Deyang, Sichuan, China
The First People's Hospital of Guangyuan
Guangyuan, Sichuan, China